Abacavir and Lamivudine
- Generic Name
- Abacavir and Lamivudine
- Indication
本品可与其它抗逆转录病毒药联合用药，适用于治疗HIV-1感染。
Dual Therapy With Boosted Darunavir + Dolutegravir
Phase 3
Completed
- Conditions
- HIV-Infection
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 269
- Registration Number
- NCT02486133
- Locations
- 🇩🇪
Klinikum rechts der Isar, Munich, Germany
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00772902
- Locations
- 🇪🇸
Gilead Sciences, Madrid, Spain
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2010-08-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 159
- Registration Number
- NCT00615810
- Locations
- 🇬🇧
Gilead Sciences, Granta Park, Cambridge, Abington, United Kingdom
Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT00318123
- Locations
- 🇪🇸
Hospital Central de Asturias, Asturias, Oviedo, Spain
🇪🇸Hopsital Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Virgen Macarena, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath